
<PAGE>
================================================================================

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                  ------------

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 22, 2004


                          Eyetech Pharmaceuticals, Inc.
- --------------------------------------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

<TABLE>
<S>                                <C>                      <C>
          Delaware                     000-50516                 13-4104684
- ------------------------------     ---------------------    --------------------
(State or Other Jurisdiction          (Commission             (I.R.S. Employer
     of Incorporation)               File Numbers)          Identification No.)
</TABLE>


<TABLE>
<S>                                                         <C>
                  3 Times Square, 12th Floor
                         New York, NY                               10036
- --------------------------------------------------------    --------------------
           (Address of Principal Executive Offices)               (Zip Code)
</TABLE>


       Registrant's telephone number, including area code: (212) 824-3100


- --------------------------------------------------------------------------------
          (Former name or former address, if changed since last report)

     Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

     [ ]   Written communications pursuant to Rule 425 under the Securities Act
           (17 CFR 230.425)

     [ ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act
           (17 CFR 240.14a-12)

     [ ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the
           Exchange Act (17 CFR 240.14d-2(b))

     [ ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the
           Exchange Act (17 CFR 240.13e-4(c))

================================================================================


<PAGE>
ITEM 7.01. REGULATION FD DISCLOSURE

     On December 22, 2004, Eyetech Pharmaceuticals, Inc. announced the list
price for Macugen(R) (pegaptanib sodium injection). The full text of the press
release announcing the list price is filed as Exhibit 99.1 to this Current
Report on Form 8-K.


<PAGE>
                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Date:  December 22, 2004             EYETECH PHARMACEUTICALS, INC.


                                     By:        /s/ Glenn P. Sblendorio
                                              ----------------------------------
                                     Name:    Glenn P. Sblendorio
                                     Title:   Senior Vice President, Finance and
                                              Chief Financial Officer


<PAGE>
                                  EXHIBIT INDEX

<TABLE>
<CAPTION>
Exhibit No.      Description
- -----------      -----------
<S>              <C>
99.1             Press release dated December 22, 2004, of Eyetech
                 Pharmaceuticals, Inc. announcing the list price of Macugen(R)
                 (pegaptanib sodium injection)
</TABLE>


